Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 5.24
SNSS's Cash to Debt is ranked lower than
64% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. SNSS: 5.24 )
Ranked among companies with meaningful Cash to Debt only.
SNSS' s 10-Year Cash to Debt Range
Min: 2.18   Max: No Debt
Current: 5.24

Equity to Asset 0.41
SNSS's Equity to Asset is ranked lower than
76% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SNSS: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
SNSS' s 10-Year Equity to Asset Range
Min: -3.31   Max: 0.89
Current: 0.41

-3.31
0.89
F-Score: 2
Z-Score: -15.71
M-Score: -4.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -976.22
SNSS's Operating margin (%) is ranked lower than
79% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. SNSS: -976.22 )
Ranked among companies with meaningful Operating margin (%) only.
SNSS' s 10-Year Operating margin (%) Range
Min: -64863.64   Max: -169.03
Current: -976.22

-64863.64
-169.03
Net-margin (%) -817.70
SNSS's Net-margin (%) is ranked lower than
78% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. SNSS: -817.70 )
Ranked among companies with meaningful Net-margin (%) only.
SNSS' s 10-Year Net-margin (%) Range
Min: -74506.06   Max: -166.44
Current: -817.7

-74506.06
-166.44
ROE (%) -247.69
SNSS's ROE (%) is ranked lower than
93% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. SNSS: -247.69 )
Ranked among companies with meaningful ROE (%) only.
SNSS' s 10-Year ROE (%) Range
Min: -1198.61   Max: -57.33
Current: -247.69

-1198.61
-57.33
ROA (%) -71.36
SNSS's ROA (%) is ranked lower than
80% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. SNSS: -71.36 )
Ranked among companies with meaningful ROA (%) only.
SNSS' s 10-Year ROA (%) Range
Min: -448.13   Max: -39.99
Current: -71.36

-448.13
-39.99
ROC (Joel Greenblatt) (%) -110985.15
SNSS's ROC (Joel Greenblatt) (%) is ranked lower than
99% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. SNSS: -110985.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNSS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -138593.85   Max: -460.2
Current: -110985.15

-138593.85
-460.2
Revenue Growth (3Y)(%) -6.50
SNSS's Revenue Growth (3Y)(%) is ranked lower than
56% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. SNSS: -6.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNSS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 74.5
Current: -6.5

0
74.5
EBITDA Growth (3Y)(%) 15.90
SNSS's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. SNSS: 15.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNSS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59.5   Max: 15.9
Current: 15.9

-59.5
15.9
EPS Growth (3Y)(%) 18.70
SNSS's EPS Growth (3Y)(%) is ranked higher than
76% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. SNSS: 18.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNSS' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.4   Max: 20.5
Current: 18.7

-60.4
20.5
» SNSS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SNSS Guru Trades in Q2 2014

Steven Cohen 468,500 sh (unchged)
Jim Simons 22,886 sh (-1.41%)
First Eagle Investment 200,000 sh (-8.91%)
» More
Q3 2014

SNSS Guru Trades in Q3 2014

Jim Simons Sold Out
Steven Cohen Sold Out
First Eagle Investment Sold Out
» More
Q4 2014

SNSS Guru Trades in Q4 2014

Paul Tudor Jones 17,516 sh (New)
First Eagle Investment 1,414,276 sh (New)
» More
Q1 2015

SNSS Guru Trades in Q1 2015

Paul Tudor Jones Sold Out
First Eagle Investment 587,976 sh (-58.43%)
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.50
SNSS's P/B is ranked lower than
81% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. SNSS: 10.50 )
Ranked among companies with meaningful P/B only.
SNSS' s 10-Year P/B Range
Min: 1.01   Max: 297.5
Current: 10.5

1.01
297.5
P/S 33.20
SNSS's P/S is ranked lower than
74% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. SNSS: 33.20 )
Ranked among companies with meaningful P/S only.
SNSS' s 10-Year P/S Range
Min: 0.9   Max: 157.25
Current: 33.2

0.9
157.25
Current Ratio 2.59
SNSS's Current Ratio is ranked lower than
67% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. SNSS: 2.59 )
Ranked among companies with meaningful Current Ratio only.
SNSS' s 10-Year Current Ratio Range
Min: 0.71   Max: 12.17
Current: 2.59

0.71
12.17
Quick Ratio 2.59
SNSS's Quick Ratio is ranked lower than
63% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SNSS: 2.59 )
Ranked among companies with meaningful Quick Ratio only.
SNSS' s 10-Year Quick Ratio Range
Min: 0.71   Max: 12.17
Current: 2.59

0.71
12.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.30
SNSS's Price/Net Cash is ranked lower than
56% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. SNSS: 11.30 )
Ranked among companies with meaningful Price/Net Cash only.
SNSS' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 178.5
Current: 11.3

1.68
178.5
Price/Net Current Asset Value 11.30
SNSS's Price/Net Current Asset Value is ranked lower than
57% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 15.30 vs. SNSS: 11.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SNSS' s 10-Year Price/Net Current Asset Value Range
Min: 1.62   Max: 273.5
Current: 11.3

1.62
273.5
Price/Tangible Book 10.30
SNSS's Price/Tangible Book is ranked lower than
73% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. SNSS: 10.30 )
Ranked among companies with meaningful Price/Tangible Book only.
SNSS' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 273.5
Current: 10.3

1.6
273.5
Price/Median PS Value 4.10
SNSS's Price/Median PS Value is ranked lower than
73% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SNSS: 4.10 )
Ranked among companies with meaningful Price/Median PS Value only.
SNSS' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 15.11
Current: 4.1

0.1
15.11
Earnings Yield (Greenblatt) -31.40
SNSS's Earnings Yield (Greenblatt) is ranked lower than
87% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. SNSS: -31.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
SNSS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -32.2   Max: 16670.9
Current: -31.4

-32.2
16670.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RYIN.Germany,
Sunesis Pharmaceuticals Inc was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is an anti-cancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. In October 2014, the Company announced the results of a Phase 3, multi-national, randomized, double-blind, placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial, which enrolled 711 adult patients, was designed to evaluate the effect of vosaroxin in combination with cytarabine, most commonly used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine, and was conducted at 124 study sites in the U.S., Canada, Europe, South Korea, Australia and New Zealand. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
ciazek stock Mar 28 2015 
comment on SNSS Mar 02 2013 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Weekly CFO Buys Highlight: SNSS, INUV, CEP, CMTL, SURW Oct 09 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
cooldecency99 note on SNSS May 01 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 
Most Trade Guru Stocks: Citigroup Inc., Bank of America Corp., Alcoa Inc., Sunesis Pharmaceuticals Dec 12 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 

More From Other Websites
3:33 am Sunesis Pharma presents post hoc analysis shows promising outcomes for... Jun 01 2015
Sunesis Pharmaceuticals Announces Presentation of VALOR Trial Subgroup Analysis at ASCO 2015 Annual... May 31 2015
Sunesis Pharmaceuticals Announces Presentation of VALOR Trial Subgroup Analysis at ASCO 2015 Annual... May 31 2015
Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European... May 21 2015
Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European... May 21 2015
The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Update May 15 2015
Sunesis Pharmaceuticals Announces Presentation of VALOR Data at the 2015 ASCO Annual Meeting May 14 2015
Sunesis Pharmaceuticals Announces Presentation of VALOR Data at the 2015 ASCO Annual Meeting May 14 2015
Sunesis to Present at the 2015 UBS Global Health Care Conference May 13 2015
Sunesis to Present at the 2015 UBS Global Health Care Conference May 13 2015
10-Q for Sunesis Pharmaceuticals, Inc. May 07 2015
10-K for Sunesis Pharmaceuticals, Inc. May 06 2015
Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today May 05 2015
Sunesis reports 1Q loss May 05 2015
Sunesis reports 1Q loss May 05 2015
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2015
Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights May 05 2015
Q1 2015 Sunesis Pharmaceuticals Inc Earnings Release - Time Not Supplied May 05 2015
Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights May 05 2015
Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2015 Financial Results and... Apr 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK